Drugs / d1309
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004307 | Dec 1999 → ? | inborn disorder of amino acid metabolism | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d1309 | “Part B is a dose escalation study of a first-generation adenoviral vector with an E1 deletion and an E3 deletion substitution (d1309) expressing ornithine transcarbamylase (OTC).” NCT00004307 ↗ |
| Route | Intravenous | “single low, intermediate, or high dose of intravenous OTC vector” NCT00004307 ↗ |